Search

Displaying results 5361 - 5370 of 9333 in total
  1. Drug

    Vibriolysin

    go.drugbank.com/drugs/DB05135
    Experimental

    Vibriolysin is a proteolytic enzyme secreted by the marine microorganism Vibrio proteolyticus. … It is a new agent for enzymatic debridement, shown to rapidly and thoroughly hydrolyze burn wound eschar within full-thickness wounds.

  2. Drug

    TPMPA

    go.drugbank.com/drugs/DB16754
    Experimental

    [A245303] GABA<sub>C</sub> receptors are found primarily in the retina, although they may be present in other tissues, including the hippocampus, spinal cord, superior colliculus, pituitary and the gut … [A245308,A245313] TPMPA is used as a pharmacological probe for the investigation of GABA<sub>C</sub> receptor function.[A245313]

  3. Drug

    APL-9

    go.drugbank.com/drugs/DB16460
    Investigational

    APL-9 is an investigational drug intended to centrally control the complement cascade at C3, potentially treating various diseases caused by excessive or uncontrolled complement activation. … It shares the same mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life.

  4. Drug

    SAR445136

    go.drugbank.com/drugs/DB17708
    Investigational

    [A259063] It was formerly investigated for the treatment of beta-thalassemia, and it is currently being investigated for the treatment of sickle cell disease.[L46148] … It consists of autologous CD34+ hematopoietic stem precursor cells (HSPC) modified ex vivo by zinc finger nucleases (ZFN) that target the BCL11A gene erythroid-specific enhancer (ESE) to increase endogenous

  5. Drug

    MVC-COV1901

    go.drugbank.com/drugs/DB15854
    Investigational

    The vaccine candidate contains a perfusion form of the SARS-Cov2 recombinant spike protein. … As of September 2020, the vaccine candidate is in Phase 1 clinical trials to assess its safety and immunogenicity (NCT04487210).

  6. Drug

    Zunsemetinib

    go.drugbank.com/drugs/DB16502
    Investigational

    Additionally, ATI-450 was studied in a terminated trial (NCT05511519) to treat patients with psoriatic arthritis. … Zunsemetinib is being investigated in a new clinical trial (NCT06374459) for the treatment of hormone receptor-positive and HER2-negative metastatic breast cancer with bone metastasis.

  7. Drug

    Benidipine

    go.drugbank.com/drugs/DB09231
    Investigational

    Benidipine has the formula 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine-dicarboxylic acid methyl 1-(phenylmethyl)-3-piperidinyl ester hydrochloride.

  8. Drug

    Brifentanil

    go.drugbank.com/drugs/DB09172
    ExperimentalIllicit

    The effects of brifentanil are very similar to those of alfentanil, with strong but short lasting analgesia and sedation, and particularly notable itching and respiratory depression. … This drug is classified as an opioid analgesic and was developed in the early 1990s.

  9. Drug

    PSN9301

    go.drugbank.com/drugs/DB05001
    Experimental

    PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes. … PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for meal-related dosing.

  10. Drug

    Mitoxantrone

    go.drugbank.com/drugs/DB01204
    ApprovedInvestigational

    An anthracenedione-derived antineoplastic agent.